EPZ-5676: Potent and Selective DOT1L Inhibitor for Epigenetic Cancer Research

Executive Summary: EPZ-5676 is a highly selective DOT1L inhibitor with an IC50 of 0.8 nM and a Ki value of 80 pM, providing over 37,000-fold selectivity against other methyltransferases (APExBIO product data). It blocks H3K79 methylation, leading to marked downregulation of MLL-fusion target genes and cytotoxicity in acute leukemia cell models (Ishiguro et al., 2025). EPZ-5676 operates as a competitive SAM binding site inhibitor, inducing conformational changes in DOT1L and opening a hydrophobic pocket. In vivo, administration in nude rat MV4-11 xenograft models at 35–70 mg/kg/day intravenously for 21 days resulted in complete tumor regression without significant toxicity. The compound is insoluble in water but highly soluble in DMSO (≥28.15 mg/mL) and ethanol (≥50.3 mg/mL with ultrasonic assistance), and should be stored at -20°C (APExBIO).

Biological Rationale

DOT1L (Disruptor of Telomeric Silencing 1-Like) is an evolutionarily conserved histone methyltransferase enzyme. It specifically methylates lysine 79 on histone H3 (H3K79), a post-translational modification linked to active gene transcription (DOI:10.1016/j.canlet.2025.217941). In acute leukemias with MLL (Mixed Lineage Leukemia) gene rearrangements, DOT1L’s methyltransferase activity is hijacked to aberrantly activate leukemogenic gene expression programs. In multiple myeloma (MM), DOT1L is a critical epigenetic dependency, as shown by genome-scale CRISPR screens and pharmacological inhibition studies. DOT1L inhibition disrupts the expression of proliferation and survival genes, notably by suppressing IRF4-MYC signaling, activating interferon (IFN)-regulated genes, and inducing cell cycle arrest and apoptosis. This distinct mechanism renders DOT1L a preferential target in epigenetic cancer therapy (Ishiguro et al., 2025).

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ-5676 (A4166, by APExBIO) is a competitive inhibitor that targets the S-adenosyl methionine (SAM) binding pocket of DOT1L. It binds with high affinity, inducing a conformational shift that exposes a hydrophobic pocket beyond the amino acid portion of SAM (APExBIO). This structural rearrangement underpins its selectivity and potency. The compound exhibits an IC50 of 0.8 nM and Ki of 80 pM in biochemical enzyme assays. EPZ-5676 does not significantly inhibit other histone methyltransferases (CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, WHSC1/1L1), exhibiting >37,000-fold selectivity. In cell-based assays, EPZ-5676 robustly inhibits H3K79 methylation, leading to downregulation of MLL-fusion target genes and potent cytotoxicity, with an IC50 of 3.5 nM in MV4-11 cells after 4–7 days of exposure. The antiproliferative effect is linked to DNA damage response activation and enhanced expression of IFN-regulated genes (Ishiguro et al., 2025).

Evidence & Benchmarks

• EPZ-5676 inhibits DOT1L with an IC50 of 0.8 nM and Ki of 80 pM in enzyme assays (APExBIO).
• Demonstrates over 37,000-fold selectivity against other methyltransferases, including CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, and SMYD2/3 (APExBIO).
• Inhibits proliferation of MV4-11 MLL-rearranged leukemia cells with an IC50 of 3.5 nM (4–7 day treatment) (APExBIO).
• Suppresses H3K79 methylation and downregulates MLL-fusion target genes, resulting in cell cycle arrest and apoptosis in acute leukemia and multiple myeloma models (Ishiguro et al., 2025).
• In vivo, intravenous dosing at 35–70 mg/kg/day for 21 days in nude rats with MV4-11 xenografts led to complete tumor regression without significant toxicity or weight loss (APExBIO).
• DOT1L inhibition by EPZ-5676 upregulates IFN-regulated genes and enhances the anti-myeloma effect of lenalidomide in combinatorial regimens (Ishiguro et al., 2025).
• EPZ-5676’s mechanism and workflow integration are further detailed in DOT1L Inhibitor EPZ5676: Precision Epigenetic Modulation, which this article extends by providing updated clinical and mechanistic benchmarks.
• For a mechanistic deep dive, see DOT1L Inhibitor EPZ-5676: Pioneering Mechanistic Precision; this article updates those findings to include recent immuno-epigenetic insights from Ishiguro et al. 2025.

Applications, Limits & Misconceptions

EPZ-5676 is primarily used in biochemical DOT1L enzyme inhibition assays and cell proliferation studies in hematological malignancy models. Its high selectivity and potency make it an industry standard for dissecting epigenetic dependencies in MLL-rearranged leukemia and multiple myeloma. The inhibitor is being explored for immune-epigenetic modulation, specifically to potentiate responses to immunomodulatory drugs like lenalidomide in MM (Ishiguro et al., 2025). However, its efficacy is context-dependent, and several misconceptions persist regarding its use and scope.

Common Pitfalls or Misconceptions

• EPZ-5676 is not effective in malignancies without DOT1L dependency or MLL rearrangements; its utility is limited outside these molecular contexts.
• The compound is insoluble in water and must be dissolved in DMSO or ethanol with ultrasonic assistance for experimental use.
• Long-term storage of solutions above -20°C or repeated freeze-thaw cycles can degrade compound potency.
• DOT1L inhibition does not universally sensitize all tumor types to immunotherapy; evidence is strongest in multiple myeloma and MLL-rearranged leukemia models.
• Off-target effects are minimal due to high selectivity, but cross-reactivity should be empirically confirmed if novel methyltransferase targets are involved.

Workflow Integration & Parameters

EPZ-5676 (A4166) is supplied as a solid (MW: 562.71) and should be dissolved in DMSO (≥28.15 mg/mL) or ethanol (≥50.3 mg/mL with ultrasonic assistance) for stock preparation. It is insoluble in water. For cell-based assays, typical working concentrations range from 1–100 nM, with 3.5 nM achieving robust antiproliferative effects in MV4-11 cells over 4–7 days. Stock solutions are stable for several months at -20°C. Avoid repeated freeze-thaw cycles and prolonged exposure above -20°C. In vivo studies in rat xenografts used intravenous administration at 35–70 mg/kg/day for 21 days, which resulted in complete tumor regression without observed toxicity. Refer to the DOT1L inhibitor EPZ-5676 product page for detailed handling protocols and safety data. For troubleshooting and advanced experimental design, see EPZ5676: Deep Dive into DOT1L Inhibition and Epigenetic Control, which this article expands by offering updated immuno-oncology data.

Conclusion & Outlook

EPZ-5676, as supplied by APExBIO, is a potent, selective, and well-characterized DOT1L inhibitor that has set new benchmarks in epigenetic cancer research. Its unique mode of action and high selectivity profile make it an essential tool for dissecting DOT1L’s role in gene regulation, especially in MLL-rearranged leukemia and multiple myeloma. Recent studies highlight its promise not only as an antiproliferative agent but also as an immune-modulatory adjunct, enhancing efficacy of standard-of-care therapies. Continued translational research will clarify additional therapeutic contexts and potential combinatorial strategies. Researchers are advised to follow best practices for compound handling and to remain aware of its mechanistic boundaries.